Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Nov;89(3):525-32.
doi: 10.1111/j.1476-5381.1986.tb11152.x.

Role of cyclic GMP in the modulation by endothelium of the adrenolytic action of prazosin in the rat isolated aorta

Role of cyclic GMP in the modulation by endothelium of the adrenolytic action of prazosin in the rat isolated aorta

I Alosachie et al. Br J Pharmacol. 1986 Nov.

Abstract

The effect of endothelium on the adrenolytic action of prazosin was studied in the rat isolated aorta. Prazosin showed a non-competitive type of antagonism in preparations with intact endothelium while in preparations where endothelium had been removed, prazosin at concentrations between 0.3 nM-10 nM acted as a competitive antagonist. Methylene blue, used to decrease tissue levels of guanosine 3':5'-cyclic monophosphate (cyclic GMP), converted prazosin from a non-competitive antagonist into an apparently competitive antagonist in the presence of endothelium. Increasing tissue levels of cyclic GMP by incubation with 8-bromo-cyclic GMP converted prazosin from an apparently competitive antagonist into a non-competitive antagonist in the absence of endothelium. Analysis of concentration-response curves for noradrenaline in the presence and absence of endothelium showed that the affinity for noradrenaline was the same but the efficacy, measured by estimating the receptor reserve, was not; it was lower in the presence than in the absence of endothelium. It was concluded that the change in the mode of antagonism of prazosin after endothelium removal could be related to an alteration in the efficacy of the agonist, brought about by a change in the tissue levels of cyclic GMP.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Biochim Biophys Acta. 1984 Jun 13;773(1):83-90 - PubMed
    1. Annu Rev Pharmacol Toxicol. 1984;24:175-97 - PubMed
    1. Br J Pharmacol. 1984 Dec;83(4):903-8 - PubMed
    1. Clin Sci (Lond). 1985;68 Suppl 10:65s-71s - PubMed
    1. J Pharmacol Exp Ther. 1985 Mar;232(3):682-7 - PubMed

Publication types

LinkOut - more resources